Mouhamed Abou-Ismail, MD
Hematology & Oncology · Rochester, NYNPI 1336553676
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,289 of the $16,223 with a category attached, or 81.9%. 14 manufacturers reported payments, led by Sanofi at 58.4% of the total.
Across 37 payments — averaging $438.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$9K
- Genentech USA, Inc.$3K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Novo Nordisk$750
- Sanofi-aventis U.S. LLC$128
- Genentech, Inc.$122
- plus $262 from 8 others
Across 143 payments — averaging $1957.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$113K
- Takeda Pharmaceuticals U.S.A., Inc.$91K
- Principia Biopharma Inc.$39K
- AstraZeneca$36K
What the payments were for
- Consulting fees$13,28982%
- Grants$7505%
- Travel & lodging$1121%
- Food & beverage$2,07313%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 17 | $9,467 |
| Genentech USA, Inc. | 6 | $3,370 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $2,124 |
| Novo Nordisk | 1 | $750 |
| Sanofi-aventis U.S. LLC | 1 | $128 |
| Genentech, Inc. | 1 | $122 |
| AstraZeneca | 2 | $91 |
| Eisai Inc. | 1 | $60 |
| Ipsen Biopharmaceuticals, Inc | 1 | $23 |
| Karyopharm Therapeutics Inc. | 1 | $22 |
| Incyte Corporation | 1 | $21 |
| Puma Biotechnology, Inc. | 1 | $19 |
| Dova Pharmaceuticals | 1 | $13 |
| Boehringer Ingelheim | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,223 in reported general payments places this provider in the 80th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 29 | $21,678 |
| XareltoRivaroxaban | 16 | $10,526 |
| Hydroxyurea | 16 | $351 |
| Prednisone | 16 | $50 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Rochester
- Alex SpyropoulosRochester$633K
- Adrienne VictorRochester$143K
- Brea LipeRochester$129K
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Francis ArenaLake Success$1M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
- Perry CookBrooklyn$803K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.